Shattuck Labs

About:

Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.

Website: http://www.shattucklabs.com/

Top Investors: Fidelity, Emerson Collective, Avidity Partners, Janus Henderson Investors, Redmile Group

Description:

Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.

Total Funding Amount:

$225M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Austin, Texas, United States

Founded Date:

2016-01-01

Contact Email:

contact(AT)shattucklabs.com

Founders:

Josiah Hornblower, Taylor Schreiber

Number of Employees:

101-250

Last Funding Date:

2023-12-21

IPO Status:

Public

Industries:

© 2025 bioDAO.ai